Skip to main content
Premium Trial:

Request an Annual Quote

Waters Q3 Revenues Up, Income Down

NEW YORK, Oct. 22 (GenomeWeb News) - Waters reported revenues of $230.4 million for the third quarter today, up from $216.0 million for the same period last year.


The Milford, Mass., instruments company had net income of $36.4 million, compared to $39.0 million for the same period last year.


For the quarter, R&D expenses increased to $15.1 million, from $13.6 million in the same period last year.


The company said its results for the quarter include "restructuring and other incremental costs and adjustments recorded in relation to the Company's reorganization of the HPLC and mass spectrometry businesses, and restructuring charges relating to the acquisition of the rheology business of Rheometric Scientific." Additionally, they reflect charges for in-process R&D that relate to the acquisition of Creon Lab Control, the company said.


As of Sept. 30, Waters had $288.1 million in cash and cash equivalents, up from $263.3 million at the end of 2002.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.